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Available online 26 July 2016Metallo-β-lactamases (MBLs) catalyse the hydrolysis of almost all β-lactam antibacterials including the latest
generation carbapenems and are a growing worldwide clinical problem. It is proposed that MBLs employ one
or two zinc ion cofactors in vivo. IsolatedMBLs are reported to use transitionmetal ions other than zinc, including
copper, cadmium and manganese, with iron ions being a notable exception. We report kinetic and biophysical
studies with the di-iron(II)-substituted metallo-β-lactamase II from Bacillus cereus (di-Fe(II) BcII) and the clini-
cally relevant B1 subclass Verona integron-encoded metallo-β-lactamase 2 (di-Fe(II) VIM-2). The results reveal
that MBLs can employ ferrous iron in catalysis, but with altered kinetic and inhibition proﬁles compared to the
zinc enzymes. A crystal structure of di-Fe(II) BcII reveals only small overall changes in the active site compared
to the di-Zn(II) enzyme including retention of the di-metal bridging water; however, the positions of the
metal ions are altered in the di-Fe(II) compared to the di-Zn(II) structure. Stopped-ﬂow analyses reveal that
the mechanism of nitroceﬁn hydrolysis by both di-Fe(II) BcII and di-Fe(II) VIM-2 is altered compared to the di-
Zn(II) enzymes. Notably, given that the MBLs are the subject of current medicinal chemistry efforts, the results
raise the possibility the Fe(II)-substituted MBLs may be of clinical relevance under conditions of low zinc avail-
ability, and reveal potential variation in inhibitor activity against the differently metallated MBLs.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).Keywords:
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More than 70 years after their ﬁrst clinical application, theβ-lactams
remain the most important antibacterials in use [1]. β-Lactamases con-
stitute an important mode of resistance to β-lactam antibacterials by
catalysing hydrolysis of the β-lactam ring to give inactive β-amino
acid products [2–5]. In mechanistic terms, β-lactamases are divided
into two classes, i.e. those that employ a nucleophilic serine residue
(serine β-lactamases (SBLs), Ambler classes A, C, and D) and those re-
quiring metal ions for hydrolysis (metallo-β-lactamases (MBLs), Am-
bler class B) [6,7]. The MBLs pose an important threat to the continued
use of β-lactam antibacterials through their ability to hydrolyse almoste-β-lactamase; BcII, metallo-β-
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. This is an open access article underall known types, with the sole exception of the monobactams [8,9].
The metallo-β-lactamase II from Bacillus cereus (BcII) was the ﬁrst
MBL for which a crystal structure was solved; this structure revealed
the MBL fold as a hitherto unrecognised and widely distributed metal-
binding enzyme superfamily [10]. The true MBLs, i.e. those catalysing
β-lactam hydrolysis, are further divided into three subclasses, B1, B2,
and B3. Both B1 and B3 enzymes bind two Zn(II) ions in their native
state, with the exception of the B3 enzyme GOB, which can exhibit ac-
tivity when a single Zn(II) ion is bound [11], whereas B2 enzymes
bind one Zn(II) ion and are inhibited through binding of a second ion
[12,13]. The active site of the B1MBLs is characterised by two zinc coor-
dination sites. One zinc ion, Zn1, is coordinated by three histidine resi-
dues, His116, His118 and His196, constituting Site 1; the other, Zn2, is
coordinated by an aspartate, cysteine and histidine trio of ligands,
Asp120, Cys221 andHis263, constituting Site 2 (BBL numbering scheme
used throughout [14]). A water molecule, proposed to be a hydroxide
ion, Wat1, bridges the two metal centres while an additional ‘terminal’
water molecule, Wat2, is bound to Zn2 (Fig. 1) [15].
The true MBLs exhibit promiscuity in transition metal binding and
the alternatively metallated states can retain catalytic activity [17–20].
The promiscuous metal binding of BcII has been demonstrated through
the restoration of catalytic activity to the apo-enzyme by the addition of
cadmium(II), cobalt(II) or manganese(II) salts, which manifest varying
levels of catalytic efﬁciency [17]. Co(II)-substituted BcII and Verona
integron-encoded metallo-β-lactamase 2 (VIM-2) have been utilisedthe CC BY license (http://creativecommons.org/licenses/by/4.0/).
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Fig. 1.Outline catalyticmechanism for theB1 subclassMBLs illustratedwith a cephalosporin substrate. Hydrolysis is proposed to occur via nucleophilic attack of a di-Zn(II)-bridgingwater/
hydroxide onto theβ-lactam ring carbonyl and likely proceeds through a tetrahedral intermediate (not shown). Depending on the substrate-enzyme combination, evidence for an anionic
intermediate (shown in parentheses) is sometimes observed. Numbers indicate the absorbance wavelength λmax of the corresponding assigned species present during the hydrolysis of
nitroceﬁn. The protein image is a view from a structure of the B1 MBL BcII (from B. cereus, PDB accession code: 4C09) [16]. The di-Zn(II) ion-binding enzyme exhibits two metal binding
sites: Zn1 is coordinated byHis116, His118 andHis196 at site 1, while Zn2 is coordinated by Asp120, Cys221 andHis263 at site 2.Wat1 bridges the twometal centreswhile a second apical
water, Wat2, coordinates Zn2. The protonation states of the waters are uncertain, though it is proposed that a metal-bound hydroxide acts as the nucelophile.
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been characterised [20,21]. Furthermore a class B3 MBL, L1, is active
with a di-Cu(II)-bound centre [18]. A notable exception are iron ions; al-
though the activity of an assigned FeZn L1 enzyme has been demon-
strated [22], no or negligible levels of activity have been reported with
enzymes binding solely iron as a cofactor [11,23,24].
In addition to the trueMBLs,MBL fold proteins constitute a superfam-
ily whose members exhibit diversity in both their metal binding prefer-
ences and their catalytic functionality [13]. MBL fold proteins include
di-zinc MBL fold enzymes acting on small-molecule substrates such as
glyoxalase II, methyl parathion hydrolase from Pseudomonas sp., and N-
acyl homoserine lactone hydrolase from Bacillus thuringensis [25–27]. A
further subset of MBL fold enzymes is involved in RNA processing and
DNA repair, for example tRNA ribonuclease Z from E. coli and the
human cleavage/polyadenylation speciﬁcity factor, CPSF73, and DNA
cross-link repair protein, sensitive to nitrogen mustard, SNM1 [28–30].
The MBL fold is able to accommodate both mono- and di-ferrous iron
binding. Iron-binding MBL fold proteins can exhibit oxidoreductase or
hydrolase activities; examples of MBL fold proteins catalysing oxidore-
ductase reactions include the di-iron rubredoxin:oxygen reductase
(ROO) from Desulfovibrio gigas and FprA fromMoorella thermoacetica as
well as the mono-iron dioxygenase ethylmalonic encephalopathy 1
(ETHE1) enzyme which is involved in the oxidative degradation of H2S
[31–34]. A recent study has also revealed that the phosphorylcholine es-
terase (Pce) from Streptococcus pneumoniae is an interesting example of
an MBL-fold hydrolase employing a di-Fe(II)-bound active site [35].
There are reported instances of both true MBLs and MBL fold pro-
teins co-purifying with iron [26,28,36]; however, the true MBLs have
been reported, by several groups, as being inactive with solely ironions [11,24,37]. These observations are interesting given the role of
iron availability in bacterial pathogenicity and that both di- and
mono-Fe(II)-bound MBL fold enzymes, and in particular the di-Fe(II)
hydrolase Pce, have been characterised as being active [35,38]. Herein
we report that trueMBLs reconstituted speciﬁcally with Fe(II) show ac-
tivity against the reporter substrate nitroceﬁn as well as the clinically
used antibiotic meropenem. A crystal structure of di-Fe(II) BcII reveals
only small changes in the active site compared to the di-Zn(II) enzyme;
amino acid side chains of the di-Fe(II) active site are superimposable on
those of a di-Zn(II) structure and the bridgingwater is retained, howev-
er the positions of the Fe(II) ions are altered. Stopped-ﬂow analyses
imply that the mechanism of nitroceﬁn hydrolysis by both di-Fe(II)
BcII and di-Fe(II) VIM-2 is altered compared to the di-Zn(II) enzymes.
Importantly, given that the MBLs are the subject of current medicinal
chemistry efforts, we demonstrate the potential for variation in inhibi-
tor activity against differently metallated species, i.e. Zn(II) and Fe(II).
The results have implications for the design of MBL inhibitors and
raise questions about the use of speciﬁc metal ions by MBL proteins in
a cellular context.
2. Materials & methods
2.1. Enzyme production
Recombinant BcII protein was produced in E. coli BL21(DE3)pLysS
cells grown at 37 °C using 2TY medium supplemented with 50 μg mL−1
ampicillin and 34 μg mL−1 chloramphenicol, as was previously reported
[39]. The cells were grown until an OD600 of 0.6–0.7 was reached and in-
duced with 0.5 mM isopropyl β-D-1-thiogalactopyranoside (IPTG). The
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centrifugation (10min, 10,000g), resuspended in 50mL Buffer A (20mM
MES pH 6.35) supplemented with 0.2 mM ZnCl2, DNAse I and
phenylmethylsulfonyl ﬂuoride (PMSF), then lysed by sonication. The ly-
sate was loaded onto an SP Sepharose column (1.5 × 12 cm with a
25 mL bed volume), which had been pre-equilibrated with Buffer A.
Bound proteins were eluted with a 0–1 M NaCl gradient in Buffer A.
The purity of the fractions was determined using SDS-PAGE analysis
and those fractions containing highly puriﬁed BcII (N95% pure by SDS-
PAGE) were concentrated by centrifugal ultraﬁltration. Concentrated
BcII was rediluted into 50 mL Buffer A and puriﬁed a second time on
the SP Sepharose column using the same protocol. Fractions containing
puriﬁed BcII were concentrated by centrifugal ultraﬁltration and the con-
centration of enzyme determined using a NanoDrop spectrophotometer
(Thermo Scientiﬁc, ε= 29,450 M−1 cm−1).
Recombinant VIM-2 with an N-terminal His-tag was produced in E.
coli BL21(DE3)pLysS cells at 37 °C using 2TY medium supplemented
with 50 μg mL−1 ampicillin and 34 μg mL−1 chloramphenicol as previ-
ously reported [40]. Cells were grown until an OD600 of 0.6–0.7 was
reached. At this point the temperaturewas lowered to 30 °C and expres-
sion was induced with IPTG (0.5 mM ﬁnal concentration). The cells
were incubated for a further 4 h at this temperature. Cells were harvest-
ed by centrifugation (10 min, 10,000g), resuspended in 50 mL lysis
buffer (50 mM Tris pH 7.5, 500 mM NaCl, 0.2% Tween 20, 5 mM im-
idazole) supplementedwith DNAse I, lysosyme and EDTA-free prote-
ase-inhibitor cocktail and lysed by sonication. The supernatant was
loaded onto a 5 mL HisTrap HP column followed by extensive wash-
ing with 50 mM Tris pH 7.5, 500 mM NaCl, 5 mM imidazole before
elution with a 20–500 mM imidazole gradient. Fractions containing
the puriﬁed VIM-2 were concentrated by centrifugal ultraﬁltration.
The resultant protein solution was injected onto a Superdex S200
column (300 mL) and eluted with 20 mM Tris pH 7.5, 200 mM
NaCl. To produce untagged enzyme, fractions containing pure His-
tagged VIM-2 were incubated overnight at 4 °C with His-tagged 3C
protease (1:100 w/w) to remove the N-terminal His-tag. In order to
remove the 3C protease together with any uncleaved protein the di-
gestion mixture was puriﬁed using a second HisTrap HP column pre-
equilibrated in 50 mM Tris pH 7.5, 500 mM NaCl, 20 mM imidazole.
The active and puriﬁed enzyme fractions as identiﬁed by SDS-PAGE
and a nitroceﬁn-based activity measurement, were pooled and concen-
trated by centrifugal ultraﬁltration. The concentrations of the puriﬁed
proteinswere determined using a NanoDrop spectrophotometer (Ther-
mo Scientiﬁc, ε= 31,400 M−1 cm−1).
2.2. Generation of apo-enzymes
Apo-BcII and apo-VIM-2 were generated using an adaptation of a
previous method [17]. Thus, di-Zn(II) binding enzyme solutions were
dialysed against three changes of N100 volumes of an EDTA-containing
solution (50 mM HEPES pH 7.5, 200 mM NaCl, 20 mM EDTA, 2 mM
TCEP·HCl) over 24 h. EDTA was removed by a second dialysis of three
changes of N100 volumes of a metal-free solution (50 mM HEPES
pH 7.5, 100 mM NaCl, 2 mM TCEP·HCl, Chelex 100) over 24 h. All dial-
yses were carried out at 4 °C using Slide-A-Lyzer® Dialysis Cassettes
(Thermo Scientiﬁc). The concentrations of the apo-enzymes were de-
termined using a NanoDrop spectrophotometer measuring absorption
at 280 nm (ε= 29,450 M−1 cm−1 and ε= 31,400 M−1 cm−1 for BcII
and VIM-2, respectively). All subsequent concentrations used in assays
were based on this measurement.
2.3. Electrospray ionisation mass spectrometry
The MS data were acquired using a Q-TOF mass spectrometer (Q-
TOF micro, Micromass, Altrincham, U.K.) interfaced with a NanoMate
(Advion Biosciences, Ithaca, NY) with a chip voltage of 1.7 kV and a de-
livery pressure 0.5 psi. The sample cone voltage was 50 V with a sourcetemperature of 100 °C. The pressure at the interface between the atmo-
spheric source and the high vacuum region was ﬁxed at 6.30 mbars.
Data were processed using MassLynx 4.0 (Waters).2.4. Stopped-ﬂow UV/Vis absorption kinetics
All metal solutions andmetal-substituted enzymes for stopped-ﬂow
kinetics were prepared at ≤40 ppm O2 using deoxygenated buffers.
Buffers used were: 50 mM HEPES pH 7.5, 200 mM NaCl; 50 mM MES
pH 6.5, 200 mM NaCl; 50 mM MES pH 5.5, 200 mM NaCl. All buffers
were treated with Chelex 100 to remove residual metal ions. Aliquots
of apo-enzyme were diluted to 100 μM by addition of reaction buffer
(1 mL ﬁnal volume). The enzyme was incubated with two equivalents
of tris(2-carboxyethyl)phosphine hydrochloride salt (TCEP·HCl), by ad-
dition of 2 μL of a 100 mM stock, for 5 min. Metal-substituted enzymes
were then produced by the addition of 3.5 equivalents of metal salt to
the apo-enzyme (3.5 μL of a 100 mM stock in buffer). 100 μM Metal-
substituted enzymewas rapidly mixed with 100 μM nitroceﬁn solution
in a 1:1 ratio at 5 °C. Spectra were recorded over 100 s using a photodi-
ode-array detector. Subsequent analysis of kinetic traceswas carried out
using Origin 8.5 [41]. Curves corresponding to substrate depletion
(390 nm) and product accumulation (485 nm) were ﬁtted by a single
exponential function,whilst 665 nmfeatureswereﬁtted by a double ex-
ponential function.2.5. Steady-state kinetics
Steady-state kinetic studies were carried out using a Pherastar FS
microplate reader and UV-Star 96 well clear microplates (Greiner Bio-
One). Samples of 1 mM apo-enzyme were pre-incubated with two
equivalents of TCEP·HCl for 5 min prior to addition of 3.5 equivalents
of the desired metal before dilution to concentrations required for ki-
netic assays. For Fe(II)-substituted enzymes, plates were prepared at
≤2 ppm O2 using deoxygenated buffer and sealed prior to absorbance
readings. Note, although we can't rule out trace contamination by
other metals (including Zn(II)) in the case of Fe(II) MBLs (and vice
versa), the different properties of the Fe(II)- and Zn(II)-substituted
MBLs imply the assignedmetallated states as being predominant. Reac-
tion progress at room temperaturewas followed bymonitoring changes
in absorbance at 485 nmand 295 nm, for nitroceﬁn andmeropenem re-
spectively [40,42]. Enzyme concentrations suitable for kinetic measure-
ments were obtained by monitoring changes in absorbance for a range
of enzyme concentrations between 30 nM and 30 pM, these are
shown in Table 1 & Table S1. Kinetic constants were determined using
the initial rate of hydrolysis (nitroceﬁn product formation or
meropenem substrate depletion) with the reaction initiated through
the addition of enzyme to pre-prepared substrate concentrations. Sub-
strate concentrations ranged between 400 μM and 0.4 μM. The
Michaelis-Menten equation was ﬁtted to data by non-linear regression
using GraphPad Prism software to calculate the Michaelis-Menten con-
stant and the limiting rate [43].2.6. Inhibition assays
Inhibition assays were carried out using nitroceﬁn as a reporter sub-
strate [40]. Enzyme concentrationswere the same as those employed in
equilibrium kinetic studies. Nitroceﬁn was used at a concentration of
10 μM. IC50 values were determined by pre-incubating the enzyme
with the inhibitor in the assay buffer at 24 °C for 5 min prior to the ad-
dition of substrate, as performed in previous studies [40,42]. Residual
enzyme activity was determined for a range of inhibitor concentrations.
Non-linear regression ﬁtting of IC50 curves was carried out using a
three-parameter dose-response curve in GraphPad Prism [43]. Errors
are expressed as: σð logIC50ÞlogIC50  IC50.
Table 1
Kinetic constants for the reaction of metal-substituted BcII and VIM-2 with nitroceﬁn. Data were ﬁtted using GraphPad Prism 5.
Enzyme Metal [E] (nM) kcat (s−1) Km (μM) kcat/Km (μM−1 s−1) Literature value kcat/Km (μM−1 s−1)
BcII Zn(II) 2 10.1 ± 0.4 12 ± 2 0.82 1.8[40]
BcII Fe(II) 2 12.5 ± 0.4 11 ± 2 1.2 –
VIM-2 Zn(II) 0.1 143 ± 3 9 ± 1 16 31.2[40]
VIM-2 Fe(II) 1 44 ± 2 32 ± 5 1.4 –
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All solutions were deoxygenated and preparation of samples and
plates was carried out inside a glovebox (Belle Technology) at b2 ppm
oxygen. A 24 mg mL−1 solution of apo-BcII in Chelex 100-treated
50 mM HEPES pH 7.5, 100 mM NaCl was supplemented with 2 mM
TCEP·HCl and 16 mM iron(II) ammonium sulfate. Crystallisation was
performed at room temperature using sitting drop vapour diffusion
methods in Cryschem 24 well plates (Hampton Research) sealed with
Crystal Clear sealing tape (Hampton Research). Crystals were obtained
in 23% PEG 3350, 0.10 M ammonium sulfate, 0.1 M Bis-Tris pH 5.5
using a 1:1 mixture of protein to well solution. Crystals appeared over
24 h. Crystals were cryo-cooled using 25% glycerol in well solution as
a cryo-protectant. Diffraction data were collected at 100 K on beamline
I02 of the Diamond Light Source, Didcot. Diffraction data were integrat-
ed and scaled using iMosﬂm and AIMLESS [44,45] followed by iterative
rounds of reﬁnement and model ﬁtting using PHENIX and Coot [46,47].
3. Results
3.1. Steady-state kinetics –MBLs are active with Fe(II)
Initial results using electrospray ionisationmass spectrometry under
non-denaturing conditions showed that the apo-formof BcII (measured:
24,951 Da, calculated: 24,961 Da) could be reconstituted by addition of
Zn(II) or Fe(II), with mass shifts of +130 and +108, corresponding to
the di-Zn(II) (measured: 25,081 Da, calculated: 25,091 Da) or di-Fe(II)
(measured: 25,059 Da, calculated: 25,069 Da) enzymes respectively.
The di-metallated enzymes were observed as the major species by
mass spectrometry after addition of ≥2.5 equivalents of metal ion.
In order to investigate whether these reconstituted enzymes exhib-
ited β-lactamase activity, we performed kinetic studies with both the
model MBL, BcII, and the clinically relevant MBL, VIM-2 [10,48].
Steady-state kinetic studies were performed using both the reporter
substrate nitroceﬁn andmeropenem, a clinically used carbapenem anti-
biotic [49], as substrates, substituting the apo-enzymewith either Zn(II)
or Fe(II) as the metal cofactor. Anaerobic conditions, employing a
glovebox (b10 ppm O2) [50,51], were used for the analysis with Fe(II)
in order to prevent its oxidation (Table 1 & Table S1 and Figs. S1 & S2).
Both apo-BcII and apo-VIM-2 displayed β-lactamase activity when
reconstituted not only with Zn(II)SO4·7H2O, as expected, but also with
(NH4)2Fe(II)(SO4)2·6H2O. Interestingly, and in contrast to literature re-
ports [23,24], inwhich no indication of attempts to control O2 availability
were reported, both Fe(II)-substituted BcII (di-Fe(II) BcII) andVIM-2 (di-
Fe(II) VIM-2) were able to efﬁciently catalyse the hydrolysis of both the
nitroceﬁn andmeropenem under conditions of low O2. The β-lactamase
activity of di-Fe(II) BcII is comparable to that of the di-Zn(II) enzyme, in
terms of kcat/Km values, with both substrates. However, in these assays
VIM-2 shows around a 10-fold lower efﬁciency with both substrates
when using the di-Fe(II) enzyme compared to the di-Zn(II) enzyme.
3.2. Stopped-ﬂow kinetics – Fe(II) alters the mechanism of β-lactam
hydrolysis
We then employed stopped-ﬂow absorption spectroscopy kinetics
to monitor the reaction of di-Zn(II) and di-Fe(II) BcII and VIM-2 in a1:1 ratio with nitroceﬁn under the same conditions. Nitroceﬁn absorbs
at 390 nm, with the sometimes observed intermediate derived from it
at 665 nm, and the hydrolysed nitroceﬁn product absorbs at 485 nm
(Fig. 1) [52–55]. Since pH-dependent variation in activity has previously
been observed with BcII, we investigated the BcII- and VIM-2-catalysed
hydrolysis of nitroceﬁn at different pHvalues, i.e. 5.5, 6.5 and 7.5 [17]. As
previously reported with di-Zn(II) BcII [56], spectral changes corre-
sponding to substrate depletion (390 nm) and product accumulation
(485 nm) were observed with both di-Zn(II) and di-Fe(II) BcII and
VIM-2 enzymes (Fig. 2 & Figs. S3–9) [56]. With di-Fe(II) BcII, although
no clear feature was observed around 665 nm in the normal absorbance
spectra, difference spectra, using the absorbance spectrum at an inter-
mediate time point as a baseline, revealed a decaying feature with a
λmax of 665 nm (Fig. 2 & Fig. S3). Note that difference spectra were
employed to identify the λmax of the feature and indicate that the fea-
ture corresponds to an independent species. In contrast, no such species
was observed in the reaction catalysed by di-Zn(II) BcII, in agreement
with previous studies (Fig. 2) [56]. A clear feature at 665 nm was ob-
served with di-Zn(II) VIM-2 and nitroceﬁn, while there are only minor
changes in absorbance at this wavelength with di-Fe(II) VIM-2 (Figs.
S7–9). Thus the observation of a visible reaction intermediate absorbing
at 665 nm depends on the particular metal-enzyme combination
employed. No hydrolysis of the substrate was observed in metal salt
supplemented buffers over the course of the enzyme-catalysed reaction
(Fig. S10).
Kinetic traces for the di-Zn(II) BcII and di-Zn(II) VIM-2 reaction time
courses were successfully ﬁtted by a single exponential function at all
pH values (Fig. 2, Figs. S4–5 and Figs. S7–9).Wewere able to successful-
ly ﬁt the changes in absorbance at 665 nm with both di-Fe(II) BcII and
di-Zn(II) VIM-2 at pH 7.5 and 6.5, and with di-Zn(II) VIM-2 at pH 5.5,
by a double exponential function. However, we were unable to success-
fully ﬁt the 665 nm absorbance trace for di-Fe(II) BcII at pH 5.5 (Fig. S4)
or the 665 nmabsorbance traces in general for di-Fe(II) VIM-2 (Figs. S7–
9) in the samemanner; this is likely due to the shallow gradients of the
traces on account of small changes observed in the absorbance at
665 nm.
The ﬁtting constants obtained for the BcII and VIM-2 catalysed reac-
tions are shown in Table 2 & Table S2, respectively. In the case of
nitroceﬁn hydrolysis catalysed by di-Zn(II) BcII, the ﬁtting constants
for substrate decay and product accumulation are consistent with a
mechanism in which a reaction intermediate is not observed. In con-
trast, the sometimes observed absorbance changes at 665 nm suggest
more than one possible mechanism. This proposal is supported by the
differing effects of pH on the di-Zn(II) and di-Fe(II) enzymes; the rate
of substrate depletion by di-Zn(II) BcII decreases at pH 7.5 compared
to pH 5.5 (2.55 s−1 vs 4.16 s−1), whereas the reverse is seen with di-
Fe(II) BcII (7.25 s−1 at pH 7.5 vs 3.88 s−1 at pH 5.5) (Table 2). In con-
trast, di-Zn(II) VIM-2 is more active at higher pH (substrate decay of
320 s−1 at pH 7.5 vs 190 s−1 at pH 5.5) while di-Fe(II) VIM-2 shows
the opposite effect, with a very low rate of substrate depletion at both
pH 7.5 and 6.5 (0.15 s−1 and 0.24 s−1, respectively) compared to that
at pH 5.5 (35 s−1) (Table S2).
Spectral analysis of the hydrolysis of nitroceﬁn by di-Zn(II) BcII
shows no evidence for an intermediate [56]. In contrast, di-Fe(II) BcII
shows a feature at 665 nm, potentially corresponding to an anionic in-
termediate (Fig. 2). The observation of an intermediate at 665 nm
with di-Fe(II) BcII strongly correlates with increasing pH, with a larger
BDC
A
390 nm 390 nm
485 nm 485 nm
665 nm
maxΔAbs
Fig. 2. Stopped-ﬂowkinetics of BcII-catalysednitroceﬁnhydrolysis. A & B. Spectral changes during the reaction of 50 μMdi-Zn(II) BcII, or di-Fe(II) BcII, respectively,with 50 μMnitroceﬁn in
a 1:1 ratio at pH 7.5 and 5 °C. Difference spectra of absorbancewavelengths 300–750 nm from 0.3–1.2 s using absorbance at 0.3 s as a baseline. Arrows indicate growth or decay of peaks. C
&D. Time course of the reaction of 50 μMdi-Zn(II) BcII, or di-Fe(II) BcII, respectively,with 50 μMnitroceﬁn in a 1:1 ratio of enzyme to substrate at pH7.5 and 5 °C. Absorbance traces at 390,
485 and 665 nm. Dashed lines indicate ﬁtting curve traces.
189S.T. Cahill et al. / Journal of Inorganic Biochemistry 163 (2016) 185–193change in absorbance amplitude at pH 7.5 (ΔAbsmax at pH 7.5 is 0.25
compared to ΔAbsmax at pH 6.5 and 5.5 of 0.15 and 0.05, respectively,
Fig. 2 & Figs. S4–5). The decay of the 665 nm feature with di-Fe(II) BcII
is slower than product accumulation, suggesting that di-Fe(II) BcII
might employ a branched reaction pathway as an alternative to the typ-
ically proposed linear pathway proceeding through an anionic interme-
diate (Fig. 4). Data ﬁtting using the Kintek Explorer package [57] was
unable to distinguish between linear and branched pathways (Fig.
S11), but in bothﬁttings the decay of the intermediate specieswas iden-
tiﬁed as the rate-limiting step (k3 and k4 in Tables S4 and S5, respective-
ly). Although intermediate decay is apparently rate limiting, a negligible
amount of intermediate is seen at pH 5.5. This may be explained either
by a branched pathway, in which the branch with no intermediate isTable 2
Analysis of the reaction of di-Zn(II) and di-Fe(II) BcII with nitroceﬁn in a 1:1 ratio. Fitting
constants are obtained from analysis of reaction time courses seen in Fig. 1 & Figs. S4–5.
Substrate decay, product accumulation and intermediate accumulation and decay corre-
spond to absorbance features at 390, 485 and 665 nm, respectively.
Metal pH
Substrate
decay (s−1)
Intermediate
accumulation
(s−1)
Intermediate
decay (s−1)
Product
accumulation
(s−1)
Zn(II) 5.5 4.16 ± 0.01 – – 4.13 ± 0.01
Zn(II) 6.5 3.24 ± 0.01 – – 3.29 ± 0.01
Zn(II) 7.5 2.55 ± 0.01 – – 2.75 ± 0.01
Fe(II) 5.5 3.88 ± 0.01 Not ﬁtted Not ﬁtted 5.78 ± 0.01
Fe(II) 6.5 5.25 ± 0.01 18.31 ± 0.01 1.2 ± 0.1 4.27 ± 0.01
Fe(II) 7.5 7.25 ± 0.01 20.32 ± 0.01 1.4 ± 0.1 7.20 ± 0.01favoured by lower pH, or by a linear pathway in which the rate of
decay of the intermediate rises with a decrease in pH thus preventing
an observable accumulation of intermediate.
Fitting values for di-Zn(II) VIM-2, where an intermediate at 665 nm
was seen, give good support to an on pathway intermediate as observed
in studies with a similar substrate, chromacef, which is similar to
nitroceﬁn [21]. The rate of formation of this intermediate is increased
at higher pH and there is a corresponding increase in its rate of decay.
There was no appreciable change in absorbance at 665 nm with di-
Fe(II) VIM-2 at all pH values. Thus, nitroceﬁn hydrolysis by di-Zn(II)
VIM-2 proceeds through an anionic intermediatewhich is no longer ap-
parent upon substitution with Fe(II) (Fig. 4).
Collectively, the results reveal that the mechanism of hydrolysis of
nitroceﬁn by anMBLmay change onmetal substitution, as demonstrat-
ed by the observation, or not, of an intermediate species and by the in-
troduction of a branched reaction pathway (Fig. 4). Differing rates of
reaction with different enzyme, metal and pH combinations indicate
that the optimal pH for β-lactam hydrolysis is both metal- and en-
zyme-dependent, a result consistent with literature reports on MBLs
[17,58,59].
3.3. Crystallography – Di-Zn(II) BcII and di-Fe(II) BcII are structurally
similar
Having established the activity of di-Fe(II) BcII, we investigated dif-
ferences in the active site geometrywhen compared to that of the native
di-Zn(II) enzymeusing crystallography.We successfully crystallised the
Fe(II)-substituted enzyme under low oxygen conditions [60].
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sultant structure revealed a lack of metal, validating our metal-free
preparations. (Structural data not shown, since our results were identi-
cal to a reported apo-BcII structure, PDB accession code: 3I0V [61]). A
crystal structure of di-Fe(II) BcII was determined to 1.1 Å resolution. Ini-
tial phases were obtained by molecular replacement using a reported
structure for BcII complexed with two zinc ions, PDB accession code:
4C09, as a search model [16]. The 4C09 structure was used in structural
comparisons since thedata are of a comparable quality and resolution to
the di-Fe(II) data andwere obtained under similar crystallisation condi-
tions. Numerical information on data collection and reﬁnement can be
found in Table S3.
The overall structure of di-Fe(II) BcII is almost identical to that of the
di-Zn(II) enzyme with an RMSD of 0.084 Å over backbone atoms. Anal-
ysis of the active site of the di-Fe(II) structure clearly reveals the binding
of twometal centres and that the overall active site structure is retained,
notably including retention of a water molecule bridging the twometal
centres as described in almost all reported di-Zn(II)MBL structures (Fig.
3). The reﬁned metal occupancies were 1.00 for Fe1 and 0.60 for Fe2.
Some additional electron density seen in the mFo-DFc map of the di-
Fe(II) structure during reﬁnement led us to model a fraction of Cys221
as a doubly-oxidised sulfur (sulﬁnic acid) residue (20% population), as
precedented by previousworkwith BcII [61], alongside the cysteine res-
idue which formed the major population (80%) (Fig. S13).
The positions of the metal ligands in di-Fe(II) BcII are almost identi-
cal to those of the di-Zn(II) enzyme (PDB accession code: 4C09) with a
model RMSD of 0.068 Å over the active site side chain atoms. However,
there are signiﬁcant changes in the relative positions of the metal cen-
tres when compared to the di-Zn(II) structure. In Site 1 the iron is
shifted by 0.2 Å and in Site 2 it is shifted by 0.4 Å, relative to the Zn po-
sitions in the 4C09 model. In addition, in the di-Fe(II) structure both of
the ferrous ions have an additional water ligand when compared to
the di-Zn(II) structure making Site 1 pentacoordinate with a distorted
trigonal bipyramidal geometry; Site 2 is hexacoordinate with a near
perfect octahedral coordination sphere. Interestingly, the metal-metalA
C
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Fig. 3. Comparison of the active sites of di-Fe(II) BcII (1.1 Å resolution) and di-Zn(II) BcII (1.2
density (3.0 σ mFo-DFc OMIT, blue mesh). The position of the modelled hydrogen atom asso
mFo-DFc OMIT, green mesh). B. Comparison of di-Fe(II) (green) and di-Zn(II) BcII (cyan, PD
but there are clear shifts in the positions of the metal ions. In addition each of the two ferrous
the active sites of the di-Fe(II) BcII complex (1.1 Å resolution) and di-Zn(II) BcII (PDB code: 4Cdistance in the di-Fe(II) BcII structure is 3.3 Å compared to 3.7 Å as ob-
served for the di-Zn(II) structure 4C09. Further, the distance between
the ﬁrst metal centre and the bridging water molecule shortens from
1.95 Å in di-Zn(II) BcII to 1.69 Å in di-Fe(II) BcII (Fig. 3C). Additional
mFo-DFc density seen between the site of the bridging water and
Asp120 led us to model the bridgingwater ligand, Wat1, as a hydroxide
with its hydrogen positioned between its oxygen and the side chain ox-
ygen of Asp120, as shown in Fig. 3A.
3.4. Inhibition – differently metallated MBLs can respond differently to
inhibitors
MBL inhibition is a current target for medicinal chemistry [62,63].
Given the observed differences in metal binding geometries between
the di-Fe(II) and di-Zn(II) form of BcII and in the kinetic properties of
di-Fe(II) BcII and VIM-2 compared to their di-Zn(II) enzymes, we then
investigatedwhether the twometal-substituted BcII enzymesmight re-
spond differently to known MBL inhibitors (Table 3 and Fig. S12). We
were particularly interested to see if the two enzyme forms responded
differently to thiol-based MBL inhibitors, since the sulfur often bridges
the twometal centres as an analogue of the bridging water during inhi-
bition [16,64]. The di-Zn(II) and di-Fe(II) enzymes were pre-incubated
for 5 min with inhibitors before the addition of nitroceﬁn as a reporter
substrate. We used EDTA, to investigate the ability of BcII to bind the
two metals, and two sulfur-based inhibitors – thiomandelic acid [65],
which has been found to be a broad spectrum inhibitor of MBLs, and
the thioenolate ML302F, which has been shown recently to be a potent
inhibitor of B1 MBLs [66].
Under our experimental conditions, the EDTA IC50 value for di-Zn(II)
BcII was similar to that seen for the di-Fe(II) enzyme (7.5 and 4.7 mM
respectively). However, given that the afﬁnity of EDTA for Zn(II) is
higher than that for Fe(II) [67], this data suggests that the MBL active
site has a greater afﬁnity for Zn(II) ions than for Fe(II) ions, consistent
with work characterising Zn(II) ions as, at least, the preferred endoge-
nous MBL metal [68]. Interestingly, the IC50 values obtained forB
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Å resolution). A. Active site of di-Fe(II)-BcII structure shown with representative electron
ciated with the bridging hydroxide ion and its representative density are shown (3.0 σ
B Code: 4C09). The amino acid residues occupy very similar positions in both structures
ions binds an additional water molecule. BBL numbering is used throughout. C. Views of
09, 1.2 Å resolution). Numbers shown represent distances in Å.
Table 3
IC50 values for inhibitors ofmetal-substitutedBcII, obtained from ﬁtting of residual activity
plots using GraphPad Prism. The chemical structures of the inhibitors employed are
provided.
Inhibitor Metal IC50 (μM)
EDTA Zn(II) 7500 ± 300
Fe(II) 4700 ± 100
Thiomandelic acid Zn(II) 1.3 ± 0.3
Fe(II) 2.8 ± 0.8
ML302F Zn(II) 0.046 ± 0.001
Fe(II) 0.38 ± 0.08
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forms of BcII. This may be in contrast to what is expected given the
high afﬁnity of Zn(II) for sulfur ligands [68]. However, around a 10-
fold difference in IC50 was obtained with ML302F, an inhibitor shown
to exhibit a bidentate binding mode in which a sulfur atom bridges
the two metal centres while the adjacent carboxylate binds to the
metal in site 2 [66]. This differencemay arise, at least in part, as a conse-
quence of the observed shortened intermetal distance and more tightly
bound water in the di-Fe(II) BcII structure (Fig. 3C); the alternate posi-
tion and geometry of the bridging water, Wat1, maymake it more difﬁ-
cult for some sulfur ligands to bind in an analogous manner, for steric
reasons.
4. Discussion
The results reveal that the class B1 MBLs are able to bind Fe(II) and,
in contrast to previous reports [11,22–24], are active when their Zn(II)
ions are replaced by Fe(II) ions under low oxygen conditions, with the
enzymes being able to hydrolyse both the chromogenic substrate
nitroceﬁn and the clinically employed carbapenem antibiotic
meropenem. Despite differences in the active site metal binding chem-
istry, in the case of BcII, differences in the overall catalytic efﬁciencies of
di-Zn(II) and di-Fe(II) enzymes are small, whereas di-Fe(II) VIM-2 ex-
hibits around a 10-fold drop in catalytic efﬁciency with both of the test-
ed substrates. The differences between our results and previous reports
of a lack of activity for MBLswith iron likely result from oxidation of the
ferrous iron.
Stopped-ﬂow studies of reconstituted di-Fe(II) BcII with nitroceﬁn
revealed an additional absorbance feature with a λmax of 665 nm. In
some cases, previous work with nitroceﬁn, and the related substrate
chromacef, has identiﬁed an intermediate, absorbing at 665 nm, corre-
sponding to the deprotonated delocalised anion with MBLs includingE + S E.S E.P
E + S E.S E.P
E.I
E + S E.S E.PE.I
E + S E.S E.P
Di-Zn(II) BcII:
Di-Fe(II) BcII 
(Branched):
Di-Fe(II) BcII
(Linear)/
Di-Zn(II) VIM-2:
Di-Fe(II) VIM-2:
S
NO
NO2
 R =                      ;  R' =
Fig. 4. Proposed possible reaction schemes for differently metal-substituted BcII and VIM-2. Di-
Fe(II) BcII is best described by a branched mechanism. Di-Zn(II) VIM-2 manifests an on pathw
species, S, I and P, and their absorbance wavelengths, are also shown.VIM-2, IMP-1, New Delhi metallo-β-lactamase 1 (NDM-1) and L1 [21,
52–54,69–71]. Such a feature was not visible in the di-Zn(II) BcII reac-
tion spectrum, as has been previously reported [56], suggesting that
di-Fe(II) BcII may employ a different mechanism for β-lactam hydroly-
sis (Fig. 4). In contrast the on-pathway intermediate seen in nitroceﬁn
hydrolysis by di-Zn(II) VIM-2 is no longer apparent on substitution
with Fe(II).
The crystallographic results reveal that the overall geometry of the
BcII active site is retained on metal substitution with Fe(II), including
the presence of a bridging water molecule (Fig. 3). However, there are
changes in the positions of themetal centres resulting in different coor-
dination distances and angles between both the metal ligands and the
bridging water. Although it would be premature to propose any mech-
anistic consequences of the shifted metal binding sites, the results at
least raise the possibility that changes inmetal positionmay occur in ca-
talysis and indeed inhibition; emerging evidencewith non-haem Fe(II)-
dependent oxygenases suggests that changes in metal position in some
enzymes may have been underestimated to date [72–75]. In the di-
Fe(II) BcII structure, the presence of extra mFo-DFc density beside the
bridging oxygen lead us to model the bridging species as a hydroxide
ion with its hydrogen projecting towards Asp120. In addition to the es-
sentialmetal ligation, Asp120has been proposed to play additional roles
in MBL catalysis including orientating a zinc-bound bridging water to
protonate the anionic intermediate [76]. Our results suggest that
Asp120may also play a role in positioning the bridging hydroxide to at-
tack the β-lactam carbonyl in the enzyme-substrate complex.
It has previously been reported that a number of MBL enzymes can
co-purify with iron ions in the active site [26,35–37]. This is not unsur-
prising given the promiscuous ability of these enzymes to bind and ex-
hibit catalysis with a number of transition metal ions. Indeed there are
members of the MBL superfamily that bind Fe(II) in their native forms
to carry out their catalytic functions [31–33,35]. Iron is a relatively bio-
availablemetal, although not necessarily in an available reduced ferrous
form, giving rise to the possibility that Fe(II)-substitutedMBLsmay con-
stitute a proportion of the active enzyme population, especially under
conditions of relatively low Zn(II) or high Fe(II) availability [77,78].
This possibility is supported by theﬁnding that Pce, an Fe(II)-dependent
MBL-fold hydrolase is an extracellularly located protein [35,79]. We be-
lieve that the knowledge that there already exists a bacterial di-Fe(II)-
binding MBL fold enzyme that exhibits extracellular activity lends cre-
dence to our proposal that di-Fe(II)-bound true MBLs might constitute
a biologically relevant population.
The inhibitor studies reveal that in some, but not all cases, it is pos-
sible for the same inhibitor to behave differently with di-Zn(II) and di-
Fe(II) BcII (Table 3), a result consistent with the altered active site
metallo-chemistry between the di-Zn(II) and di-Fe(II) forms (Fig. 3).E + P
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Zn(II) BcII manifests no observable intermediate, while the hydrolysis of nitroceﬁn by di-
ay intermediate that is not observed with di-Fe(II) VIM-2. The proposed corresponding
192 S.T. Cahill et al. / Journal of Inorganic Biochemistry 163 (2016) 185–193The potent inhibitor ML302F exhibited a higher IC50 with di-Fe(II) BcII
than di-Zn(II) BcII [66]. Thus, it may be prudent to test MBL inhibitors
that are in clinical development against both Zn(II)- and Fe(II)-bound
MBLs, in order to identify inhibitors potent against both metallated
forms. Further, given the known promiscuity of theMBL fold, it is possi-
ble that substitution of Zn(II) for other metals may alter catalytic prop-
erties in a manner relevant to the development of resistance. In this
regard it is of interest that a recent report has highlighted the effects
of different active site metals on native compared to promiscuous reac-
tions as catalysed by MBL fold proteins [24].
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